Home » Newsletters » BioWorld Science

BioWorld Science

April 3, 1998

View Archived Issues

Company Profile: Biosource Technologies

NIH offers malaria vaccine technology for licensing

New inhibitors of cell adhesion in development at Kao

Gliatech's H3 antagonists show potential for treating obesity

Genetix cancer gene therapy approach gives promising results in preliminary studies

SuperVent phase I/II trial going well; first part of two-part study concluded

IND granted for Enzo Biochem's HGTV43 genetic antisense therapy for AIDS

Neovastat efficacy reported at AACR

Eisai files NDA for Aciphex, novel treatment for GERD and ulcers

New acne treatment option now available in Canada

Immunex and ArQule form alliance to discover new antiinflammatory drug candidates

Neurogen prepares new class of brain GABA receptor ligands

U.S. patent issues for GenVec's advanced gene therapy vectors

Centrally active adrenergic agents in development at Pierre Fabre

Pfizer discovers compounds useful as cytokine and cell adhesion molecule inhibitors

Immunomedics discovers immunoangioplasty technology, seeks corporate partners

Positive results obtained with apoptosis suppressant in heart attack

Redux adverse effects reviewed at ACC

New prenyl transferase inhibitors in development at BMS

Novel antimicrobial compounds for Clostridium infections described by Abbott

Stehlin Foundation describes new camptothecins with improved stability

Abbott/TAP discover safer LHRH antagonists

FDA approves Actonel for Paget's disease

FDA says Integrilin is approvable

Orphan Medical announces Xyrem clinical trial results

Dual-action agent for BPH developed at Zeria

CGP-60474: selective protein tyrosine kinase inhibitor for cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...